Timo Reisländer

BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors

Timo Reisländer, Emilia Puig Lombardi, Florian J. Groelly et al. · Nature Communications · 2019 · 177 citations · Full text

A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents

Sylvia Herter, Laura Morra, Ramona Schlenker et al. · Cancer Immunology Immunotherapy · 2016 · 136 citations · Full text

Chlorambucil targets <scp>BRCA</scp> 1/2‐deficient tumours and counteracts <scp>PARP</scp> inhibitor resistance

Eliana MC Tacconi, Sophie Badie, Giuliana De Gregoriis et al. · EMBO Molecular Medicine · 2019 · 35 citations · Full text

Unresectable biliary tract cancer: Current and future systemic therapy

Danmei Zhang, Klara Dorman, C. Benedikt Westphalen et al. · European Journal of Cancer · 2024 · 19 citations · Full text

Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial

Lena Weiss, Meinolf Karthaus, Jorge Riera‐Knorrenschild et al. · ESMO Open · 2022 · 17 citations · Full text